Resolute Advisors’s Teladoc Health TDOC Stock Holding History

Resolute Advisors’s Portfolio TDOC Stock Details TDOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-273	Closed	-$20K	–	135
2022 Q1	$20K	Hold	273	–	–	﹤0.01%	108
2021 Q4	$25K	Hold	273	–	–	﹤0.01%	115
2021 Q3	$35K	Hold	273	–	–	﹤0.01%	156
2021 Q2	$45K	Hold	273	–	–	0.01%	92
2021 Q1	$50K	Buy	+273	New	+$63.3K	0.01%	76

Other funds holding TDOC

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

Resolute Advisors's TDOC Position: Q2 2022 in Review

Resolute Advisors sold out of Teladoc Health (TDOC) in Q2 2022, closing a stake of 273 shares — an estimated $20K sold.

Resolute Advisors first reported a position in TDOC in Q1 2021 and held it in 5 quarters. The position peaked at $50K in Q1 2021. 551 funds tracked by Wall St. Rank hold TDOC as of Q2 2022.

Resolute Advisors reported no remaining Teladoc Health position as of Q2 2022 after selling out during the quarter.
Resolute Advisors sold 273 Teladoc Health shares in Q2 2022, an estimated $20K.
Resolute Advisors first reported a position in Teladoc Health in Q1 2021 and held it in 5 quarters.
Resolute Advisors's Teladoc Health position peaked at $50K in Q1 2021.
551 funds tracked by Wall St. Rank held Teladoc Health as of Q2 2022.

Based on Resolute Advisors's 13F filing for Q2 2022, filed 8 Aug 2022.